GRI Bio, Inc. (GRI)

NASDAQ: GRI · Real-Time Price · USD

0.740

-0.030 (-3.90%)

At close: Dec 20, 2024, 4:00 PM

0.711

-0.029 (-3.99%)

After-hours: Dec 20, 2024, 7:57 PM EST

GRI Bio Employees

GRI Bio had 4 employees as of December 31, 2023. The number of employees increased by 3 or 300.00% compared to the previous year.

Employees

4

Change (1Y)

3

Growth (1Y)

300.00%

Revenue / Employee

n/a

Profits / Employee

-$2,065,750

Market Cap

6.61M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	4	3	300.00%
Dec 31, 2022	1	-	-

Related Stocks

Company Name	Employees
Syra Health	162
PAVmed	107
Kindly MD	65
Ainos	46
Vincerx Pharma	42
Plus Therapeutics	20
ABVC BioPharma	19
Adial Pharmaceuticals	7

Employee Rankings

GRI News

15 days ago - GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
4 weeks ago - GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - GlobeNewsWire
5 weeks ago - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
2 months ago - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 - GlobeNewsWire
2 months ago - GRI Bio Announces Exercise of Warrants - GlobeNewsWire
2 months ago - GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) - GlobeNewsWire
2 months ago - GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions - GlobeNewsWire
3 months ago - GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment - GlobeNewsWire